Related Experiment Videos
[Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter
H H Gerhartz1, W Wilmanns, G Brittinger
1Medizinische Klinik III, Klinikum Grosshadern, München.
Onkologie
|February 1, 1989
Summary
This study investigated chemotherapy regimens for advanced diffuse large cell lymphoma. The COP-BLAM and IMVP-16 protocols showed effectiveness, but some patients require more aggressive treatments for durable remission.
Area of Science:
- Oncology
- Clinical Trials
- Hematology
Background:
- Diffuse large cell lymphoma (DLCL) is an aggressive non-Hodgkin lymphoma.
- Effective treatment strategies are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the remission-inducing potential of COP-BLAM followed by IMVP-16 in advanced DLCL.
- To assess the efficacy of switching to IMVP-16 for inadequately responding patients.
Main Methods:
- Prospective multicenter therapy trial involving 349 previously untreated patients (age 15-75, stage II-IV).
- Patients received COP-BLAM (5 courses) with early switch to IMVP-16 (2 courses) for poor responders.
- Restaging assessments were performed after 3 and 7 courses of chemotherapy.
Main Results:
- Overall, 59% of patients achieved complete remission (CR).
- Early switch to IMVP-16 resulted in CR for 39% of switched patients.
- Median survival was 24 months, with relapses occurring in 32 patients.
Conclusions:
- The combined COP-BLAM and IMVP-16 strategy is effective in a large, unselected group of older patients with advanced DLCL.
- Patients with delayed responses may necessitate more aggressive treatment regimens for sustained remissions.